Wealthstreet Investment Advisors LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 31,153 shares of the medical research company’s stock, valued at approximately $5,915,000.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TMO. Capital Research Global Investors increased its position in Thermo Fisher Scientific by 29.8% during the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after purchasing an additional 3,973,136 shares during the period. Janus Henderson Group PLC increased its position in Thermo Fisher Scientific by 2,058.1% during the 2nd quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after purchasing an additional 2,233,522 shares during the period. Veritas Asset Management LLP increased its position in Thermo Fisher Scientific by 44.1% during the 3rd quarter. Veritas Asset Management LLP now owns 3,503,259 shares of the medical research company’s stock worth $662,817,000 after purchasing an additional 1,072,500 shares during the period. Meritage Group LP acquired a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $201,383,000. Finally, Capital World Investors increased its position in Thermo Fisher Scientific by 6.1% during the 2nd quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after purchasing an additional 671,637 shares during the period. Institutional investors own 86.11% of the company’s stock.
In related news, CFO Stephen Williamson sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $209.26, for a total value of $1,046,300.00. Following the sale, the chief financial officer now owns 30,741 shares of the company’s stock, valued at approximately $6,432,861.66. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Patrick M. Durbin sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $217.55, for a total value of $1,305,300.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 144,327 shares of company stock worth $28,680,042. 0.49% of the stock is owned by corporate insiders.
Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) opened at $200.18 on Monday. Thermo Fisher Scientific Inc. has a 52 week low of $151.74 and a 52 week high of $226.44. The company has a quick ratio of 0.92, a current ratio of 1.35 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $80,271.26, a P/E ratio of 35.75, a P/E/G ratio of 1.47 and a beta of 1.11.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the prior year, the company earned $2.41 EPS. Thermo Fisher Scientific’s revenue was up 22.1% on a year-over-year basis. equities analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be paid a $0.17 dividend. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.34%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio is presently 10.71%.
Several research firms have issued reports on TMO. Leerink Swann reiterated an “outperform” rating and set a $200.00 target price (down previously from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday, December 4th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. BTIG Research assumed coverage on Thermo Fisher Scientific in a research note on Friday, January 5th. They set a “buy” rating and a $230.00 price target on the stock. Zacks Investment Research raised Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Finally, Barclays boosted their price target on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Two research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus target price of $220.50.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/02/12/wealthstreet-investment-advisors-llc-invests-5-92-million-in-thermo-fisher-scientific-inc-tmo-stock.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.